Regeneron To Expand US Manufacturing, Citing Commercial And Clinical Expansion

The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.

Regeneron Pharmaceuticals is the latest biopharma company to announce an investment in its manufacturing and research and development footprint in the US. But while similar moves by other firms have been viewed as part of a reaction to Trump Administration policies, Regeneron is emphasizing a more traditional reason for the investment.

Key Takeaways

Regeneron became the latest of several drug makers that have announced plans to expand their manufacturing and R&D footprints in the US

The Tarrytown, NY-based drugmaker said 22 April that it had made an agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of its commercial biologic medicines at Fujifilm’s Holly Springs, NC, campus over 10 years

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

How Much Does Biopharma Contribute To The US Economy?

19 May 2025

• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

16 May 2025

• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

13 May 2025

• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

21 May 2025

• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.